may qualify to become a CDC-certified laboratory. In principle, because all laboratories are using the same instrument/reagent system, any matrix bias in frozen or lyophilized materials should be the same for all participants. Thus, the standardization laboratory can assign target values to frozen or lyophilized secondary standard materials for use by participating laboratories to assess their calibration. The principal limitation in such an approach will be the variable response to frozen or lyophilized materials owing to different lots of reagents and to interinstrument hardware differences. Reagent-lot-specific target values for the secondary standards can be determined by having each independent lot of reagent tested by the standardization laboratory. The standardization laboratory can assay fresh serum samples and the secondary standards using its calibrated lot of reagents and the independent lot of reagents. The bias in fresh serum results between the calibrated and independent reagents will provide a lot-specific correction factor to apply to the apparent values obtained for the secondary standards with the independent lot of reagents. This system would be less complicated and less costly if the laboratories could all use the same lot of reagents with as long a shelf life as possible.
In the emergency laboratory, immunoinhibition assays for CK-MB are widely used, being technically simple and ideally suited for automation (1) . However, the presence of atypical CK-forms and adenylate kinase (EC 2.7.4.3) in serum often leads to erroneous CK-MB results by various methods such as ion-exchange chromatography and immunoinhibition (2, 3) . Corrections for the presence of these atypical forms presumably can be made by using a second precipitating antibody in the immunoprecipitation assays (4). Infarction sizes are frequently calculated from sequential measurements of CK-MB activities, but such data should be viewed with caution because of loss of specific activity of the enzyme after its release from the infarcted zone (5,6). In addition, after effective thrombolytic therapy, calculatioris of activity-based infarct sizes are overestimated (7), partly because of these losses of specific activity.
Infectious

intensive-care
patients frequently demonstrate increased catabolism of CK in serum (8), attributable to the presence in their sera of a factor able to increase the activation energy (EA) values of the catalyzed CK reaction. In these patients, mass-concentration measurements can be expected to give higher values than activityconcentration measurements.
In cases where such factors are present in the patients' serum in the early phase of an AMI, CK and CK-MB enzymatic activities may be unexpectedly low (9).
Here we compare mass and activity concentrations of CK-MB in serum, making use of commercial assays. Then we examine the relationship between mass and activity CK concentration as a function of time after the enzyme is released into the circulation.
We also have evaluated whether CK-BB and macro-CK 1, the latter frequently observed in serum of patients with cardiac diseases (3), interfered with the mass CK-MB determinations.
Finally, to understand better the biochemical nature of the low-CK phenomenon in intensive-care patients, we compared mass and activity concentrations of CK-MB in this population of patients.
Materials and Methods
Procedures CK-MB catalytic activizy. We measured total CK activity at 37#{176}C (10) in a "GEMSAEC" centrifugal analyzer (ElectroNucleonics, Caldwell, NJ 07006), using CK-NAC reagents (no. 3175; J. T. Baker, Deventer, The Netherlands).
Catalytic CK-MB activity was measured after incubating the serum samples with CK-M subunit-inhibiting antibodies (from Isoimune-CKTh; Roche Diagnostic Systems, Nutley, NJ 07110 After incubating 100 iL of serum and 100 ML of the Zero Diluent (provided in the Tandem-E CKMB II kit) with the bead in the absence of anti-M subunit antibodies at room temperature for 60 mm, we incubated again for 90 miii with 200 ML of goat antibody to IgG (dilution 1:1000). The presence of IgG-bound CK-BB was then elicited by incubating the bead in 200 ML of alkaline phosphatase reagent from the Tandem-E CKMB II kit during 30 mm at room temperature, according to the manufacturer's protocol. CK-BB. Binding of CK-BB to the Hybritech beads was evaluated by incubating 200 ML of CK-BB standard solution (diluted similarly in Zero Diluent) with the bead at room temperature for 60 mm. After three washing cycles with 2-mL portions of Wash Solution (from the Tandem-E CKMB II kit), the bead was incubated at room temperature with 200 ML of anti-B subunit antibody solution (originating from the former Hybritech Tandem CKMB kit) for 60 mm. Finally, bound alkaline phosphatase activity was detected by a procedure similar to that used in the Tandem-E CKMB II kit.
Activation energy. Activation energy of the reaction catalyzed by CK was measured according to the Arrhenius equation: in k1/k2 = EA/R (l/T1 -l/T2) (5), where k, and k2 represent catalytic activities measured at absolute temperatures T, and T2 and R is the universal gas constant (8.3 14 J . moN K-'). The standard temperature interval for determination of the apparent activation energy was 25-37 #{176}C. To measure catalytic activity at 25#{176}C and 37 #{176}C, we used a GEMSAEC centrifugal analyzer. The changes in pH of the reaction mixture caused by use of the different temperatures were too small to necessitate correction factors.
Post-transcriptional CK-MB modification. Serum sanipies were incubated for 6 h at 37 #{176}C with arylsulfatase (20 kU/L; EC 3.1.6.1, from Patella vuigata) and with sialidase (20 UIL; EC 3.2.1.18, from Clostridium perfringens), both from Sigma Chemical Co.
Patients
For this study we analyzed 49 serum samples from 21 patients admitted to our hospital because of AMI [16 men; mean age 65.9 (SD 9.3) y; five women, mean age 73.6 (SD 7.2) y]. Blood was sampled during the first three days after onset of symptoms. Twenty ostensibly healthy blood donors (mean age 42.7, SD 11.5 y) served as a control group. Ten patients (seven men, three women; mean age 64.8, SD 8.7 y) with macro-CK 1 (39 ± 28 UIL), seven suffering from unstable angina pectoris and three with a recent (one month prior to sampling) history of AMI were monitored, as were 10 patients (five men, five women; mean age 64.5, SD 6.1 y) being treated for septicemia in the Intensive Care Unit, who had very low CK (<10 UIL) activities. None of -j 
Effect of Enzyme Aging
When the specific activity of total CK was plotted vs time after onset of AM! symptoms, specific activity was seen to decrease with enzyme aging. The specific activity of serum CK-MB decreased from 0.88 (SD 0.40) U/pg during the first 12 h after onset to 0.71 (SD 0.30) U/pg (P <0.01) by the third day after onset. Also the EA value of the CK reaction correlated qualitatively with loss of specific activity. Additional incubation of AM! serum with either sialidase or sulfatase for 6 h at 37#{176}C did not significantly change CK-MB mass measurements. Table 2 these latter groups had clinical evidence of skeletal or heart muscle injury. We also studied one patient with a scintigraphically proven AMI but negative enzyme kinetics (maximum CK activity 11 UIL, CK-MB 0 UIL).
Results
Precision Data
The within-run CV for the three investigated methods was evaluated by use of a low-and a high-concentration pooled serum (Table 1 ). For the low-concentration sample CVs ranged from 3.0% to 3.7%, whereas for the highconcentration sample the imprecision of the immunoenzymometric assay was clearly higher than for the others.
CK-MB Assays Compared _________________________________
Mass concentration measurements yield a good correlation with both immunoinhibition and immunoprecipitation techniques (Figure 1) . Regression coefficients between the methods were similar: r = 0.935 for immunoenzymometric vs immunoinhibition assay and r = 0.943 for immunoenzymometric vs immunoprecipitation assay. Striking differences are observed for the values of the intercept: an extrapolated mass concentration of 0 p.g/L corresponds, respectively, to 1.1 U/L for immunoprecipitation and 9.0 U/L for immunoinhibition.
As a consequence, immunoinhibition gives significantly higher extrapolated background values for CK-MB than does immunoprecipitation.
Interterence of Atypical CK-forms
In the 10-patient group with atypical CK-forms, immunoinhibition is interfered with by atypical CK-forms, but both the immunoprecipitation and the immunoenzymomet- 
Monoclonal Antibodies
By making use of alkaline-phosphatase-labeled antibodies directed against human IgG, we could demonstrate that macro-CK 1 binds to the anti-B subunit coated beads. Absorbance measured at 405 nm correlated with the amount of macro-CK 1 present in the three serum samples we studied. However, these atypical forms were not recognized by the second enzyme-labeled antibodies of the Tandem-E CKMB II assay. Similarly, CK-BB was shown to bind on the beads in amounts linearly related to concentrations of 350 ,ugfL, but was not recognized as well by the conjugated anti-M subunit antibodies of the Tandem-E CKMB H kit. Hours after onset of retrostemal pain. #{176}Measured at37 'C. C Mean ± SD.
d P <0.01 vs initial values.
for the reference population (mean: 1.1 g/L; range: 0.8-4.2 g/L). In a patient with proven AMI who did not show any increase in serum CK and CK-MB activity in the postinfarction period, the mass concentration of CK-MB ranged between 0.6 and 3.1 g/L. To study the effect of CKdeactivating factors present in low CK serum on the binding with the monoclonal antibodies of the Tandem-E CKMB II assay, we added serum from patients with very low CK activity to equal amounts of serum from an AM! patient (CK-MB concentration 120 zgfL). After the sample was incubated for 3 h at 37 #{176}C, no significant differences in assay results were noticed, suggesting that these CKdeactivating factors are not directly involved in the binding site for the studied monoclonal antibodies.
Discussion
Statistical analysis of the three current CK-MB methods showed a good correlation between mass concentration and catalytic activity, but absolute values for CK-MB obtained by the different methods varied widely. For an equal amount of mass concentration, the immunoinhibition method gave higher CK.MB activities than did the immunoprecipitation technique, both for the low and high concentration ranges.
In the low concentration range, differences in CK-MB results may originate from the presence of atypical CKforms and adenylate kinase in serum. In this study, immunoprecipitation and immunoenzymometric assay techniques were shown not to be interfered with by macro-CK 1. Because the activity of adenylate kinase in serum is usually low (11) , as are also the activities of atypical CK-forms (2), differences between the methods are more pronounced in the lower concentration ranges.
Variance between mass and catalytic CK-MB concentration can partly be ascribed to changes in enzyme structure, which are caused by carboxypeptidase N (EC 3.4.17.3) activity (6, 12). However, activities of the latter enzyme in serum are characterized by a large inter-individual variation (13). Because of the conformational changes in the CK-MM molecule, polyclonal antibodies against CK-M subunit fall to inhibit CK-MM1 activity completely in immunoinhibition assays. As a consequence, CK-MB activity is overestimated during the second and third day after infarction (14) . Binding of CK-MB to the Hybritech Tandem-E monoclonal antibodies is not affected by carboxypeptidase N activity (15) . Theoretically, differences in sialic acid and sulfate residues may also give rise to enzyme heterogeneity (16, 17) . However, digestion with sialidase and arylsulfatase did not affect CK-MB mass-concentration measurements.
Despite published data proving that CK is denatured in serum during the second and third day after infarction (6, 18), paradoxical increases of specific activity have been described during the decline phase of post-AMI CK-MB activity (19) . Our results show a steady increase in CK-MB activation energy, which is consistent with the general concept of tissue-enzyme denaturation after release into the systemic circulation. However, the changes in specific activity are smaller than could have been expected from the data on activation energy, suggesting the induced conformational changes of CK-MB during its stay in the blood to be multifactorial. In comparison with the earlier Hybritech Tandem CKMB kit, specific CK-MB activity is higher (20) .
In contrast to the immunoinhibition method, immunoprecipitation and immunoenzymometric assays are insensitive for macro-CK 1, consistent with earlier data (4, 21) . Theoretically, extremely high concentrations of CK-BB and macro-CK 1 in serum samples can lead to saturation of the available binding sites for the B subunit on the coated beads and thus give rise to falsely negative results, but in almost all cases concentrations of CK-BB and macro-CK 1 are low (2,22) .
Owing to changes in activation energy on enzyme aging, the correlation between mass concentration and catalytic activity measured at 37 #{176}C is more nearly linear than when measured at 25 #{176}C. For infarct sizing, mass concentration measurements are therefore easier to interpret, because mass concentration of CK-MB were found. These results suggest that, in these patients' sera, specific CK-MB activity must be very high. This is consistent with earlier findings that, in these patients, CK catabolism is increased because of the presence of CK-deactivating factors (8) . In patients with AM! and unexpectedly low CK and CK-MB activities (8, 9), we therefore recommend CK-MB to be remeasured by means of an inununoassay.
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